Retension Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| RTSN | RLMD | PHAR | MIST | BBOT | TNXP | |
|---|---|---|---|---|---|---|
| Market cap | 117.23M | 330.68M | 662.48M | 88.06M | 226.09M | 103.59M |
| P/E (TTM) | — | — | 72.0 | — | — | — |
| Forward P/E | — | -7.6 | 142.9 | -0.9 | -1.0 | -0.8 |
| Price/book | -0.8 | 1.6 | 2.5 | 5.5 | 0.7 | 0.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +15.95% | +59.20% | −34.14% | −64.47% | −74.93% | −69.56% |
| Today | +15.23% | −3.13% | −2.40% | −10.98% | −4.41% | −5.92% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All RTSN news ›Falls Church’s Retension Pharmaceuticals Prices Upsized $45 Million IPO to Advance Hypertension Drug RTN-001
Retension plans to use the net proceeds, together with existing cash, to complete its Phase 2b clinical trial of RTN-001 in uncontrolled hypertension and to prepare for and advance a planned Phase 3 trial, with the remainder going to…
Retension Pharmaceuticals: PVG reports 8.3% stake
Sole voting power covers 1,002,050 shares, while power to dispose of those shares is shared, according to PVG Asset Management's ownership disclosure. - [SCHEDULE 13G] Retension Pharmaceuticals, Inc. Passive Investment Disclosure (>5%)…
Retension Pharmaceuticals: B Group reports 833K shares
B Group Capital LLC directly holds 833,333 shares of Retension Pharmaceuticals (RTSN). Stock Titan - [Form 3] Retension Pharmaceuticals, Inc. Initial Statement of Beneficial Ownership Retension Pharmaceuticals: B Group reports 833K shares…
Discontinued operations of Retension Pharmaceuticals, Inc. – NASDAQ:RTSN
Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product, RTN-001, is a next-generation, once-daily,…
Retension Pharmaceuticals CEO holds 7.07% after IPO
Transfers are restricted until 180 days after the prospectus date, with limited exceptions; 255,174 option shares are excluded from beneficial ownership. - [SCHEDULE 13D] Retension Pharmaceuticals, Inc. Major Shareholder Acquisition (>5%)…
Retension Pharmaceuticals Announces Pricing of Initial Public Offering
FALLS CHURCH, Va., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Retension Pharmaceuticals, Inc. (Nasdaq: RTSN) (“Retension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of…
Retension Pharmaceuticals' IPO charter takes effect
Strive Announces Proposed Initial Public Offering of SATS Stock Beyond Starmatter™ Earns Clean Label Project® Purity Award Retension Pharmaceuticals, Inc. (RTSN) filed its Third Amended and Restated Certificate of Incorporation with the…
Long term debt to total assets ratio of Retension Pharmaceuticals, Inc. – NASDAQ:RTSN
Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product, RTN-001, is a next-generation, once-daily,…
Net margin % of Retension Pharmaceuticals, Inc. – NASDAQ:RTSN
Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product, RTN-001, is a next-generation, once-daily,…
EBITDA per share of RETENSION PHARMACEUTICALS INC – NASDAQ:RTSN
Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product, RTN-001, is a next-generation, once-daily,…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
tradingview.com10
-
stocktitan.net9
-
financialcontent.com2
-
pluang.com2
-
247wallst.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 38 articles, not a forecast.